文献速递妇科

选择性β受体阻滞剂摄入对上皮性卵巢癌患者生存无影响

Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2016-11-16

该研究回顾性分析1999至2014年两家三级妇科肿瘤中心连续收治的801例原发上皮性卵巢癌患者,其中141例(17.6%)同时使用选择性β受体阻滞剂。结果显示,使用与未使用选择性β受体阻滞剂两组患者的无进展生存期和总生存期均无显著差异,多因素分析也未发现选择性β受体阻滞剂摄入与预后相关。

要点

  • 801例上皮性卵巢癌患者中141例(17.6%)使用选择性β受体阻滞剂。
  • 使用与未使用选择性β受体阻滞剂两组无进展生存期(27个月 vs 24个月,p=0.40)和总生存期(56个月 vs 44个月,p=0.15)无显著差异。
  • 多因素分析未发现选择性β受体阻滞剂摄入与预后相关。

核心结论

  • 选择性β受体阻滞剂摄入不影响上皮性卵巢癌患者的预后。

研究设计与样本

  • 研究纳入1999至2014年在两家三级妇科肿瘤中心连续收治的所有原发上皮性卵巢癌患者,用药情况通过病历回顾性分析。

主要发现

  • 研究队列共801例患者,其中141例(17.6%)接受选择性β受体阻滞剂。
  • 未使用选择性β受体阻滞剂患者的中位年龄为56岁(范围19-90岁),使用选择性β受体阻滞剂患者为64岁(范围41-84岁),p<0.001。
  • 使用选择性β受体阻滞剂患者中63.8%实现肿瘤完全切除,未使用者为74.2%,p=0.012。
  • 未使用选择性β受体阻滞剂患者术后严重并发症(Clavien-Dindo分类)较少(18.8% vs 29.0%,p=0.003)。
  • 使用与未使用选择性β受体阻滞剂两组无进展生存期分别为24个月和27个月(p=0.40),总生存期分别为44个月和56个月(p=0.15),均无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Some authors have claimed a significant impact of β-blocking agents on outcome in epithelial ovarian cancer (EOC). This study investigated the impact of concurrent medication with selective beta blockers (SBB) in patients undergoing primary treatment for EOC. METHODS: The study included all consecutive patients with primary EOC treated in two tertiary gynecological-oncologic units between 1999 and 2014. Medication was retrospectively analyzed by chart review. RESULTS: The study cohort comprised 801 patients, of whom 141 (17.6%) had received SBB. Median age of patients without SBB medication was 56years (range: 19-90years) and 64years (range: 41-84years) in patients taking SBB (p<0.001). The main prognostic factor FIGO stage did not differ between both cohorts. 63.8% of patients taking SBB underwent complete tumor resection compared to 74.2% of patients without SBB (p=0.012). Patients without SBB experienced less severe post-operative complications according to the Clavien-Dindo classification (18.8% vs 29.0%; p=0.003). Between the both groups without and with SBB intake, PFS and OS did not differ significantly (PFS: 27months and 24months, p=0.40; OS: 56months and 44, p=0.15). Multivariate analyses did not yield any association between SBB intake and prognosis but confirmed well-known prognostic factors. CONCLUSIONS: Intake of selective β-blockers did not influence the prognosis of patients with EOC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Heitz F, Hengsbach A, Harter P, et al. Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2016. PMID: 27863705. doi:10.1016/j.ygyno.2016.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。